BioCentury
ARTICLE | Company News

B&C Biopharm, XTL deal

March 3, 2003 8:00 AM UTC

XTL exercised an option under a 2002 deal to acquire development and commercialization rights to a series of preclinical hepatitis C virus (HCV) compounds from B&C. XTL will have exclusive worldwide r...